BriaCell announces updated Phase 2 survival data fro Bria-IMT

BriaCell (BCTX) Therapeutics announced updated Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, in combination with an immune check point inhibitor. The data show a meaningful survival advantage in heavily pretreated metastatic breast cancer patient subtypes: Triple negative breast cancer: median overall survival of 13.9 months vs. 11.8 months for antibody drug conjugate Trodelvy and 6.9 months single agent chemotherapy data. BriaCell’s median OS has improved from 11.4 months last reported at ASCO in June 2025. Hormone receptor positive: median overall survival of 17.3 months vs. 14.4 months for Trodelvy and 11.2 months in single agent chemotherapy data. “We are thrilled to see our Bria-IMT regimen outperform established benchmarks like Trodelvy in TNBC and HR+ MBC patients,” stated William Williams, CEO. “BriaCell’s patients had failed a median of six prior therapies, underscoring the potential clinical impact of our novel immunotherapy. We look forward to validating these findings in our ongoing pivotal Phase 3 study with overall survival as its primary endpoint.” The Phase 2 Bria-IMT study enrolled 54 heavily pre-treated metastatic breast cancer patients who received the Bria-IMT regimen plus checkpoint inhibitor. Of these 54 patients, 37 received the same formulation currently being used in BriaCell’s ongoing pivotal Phase 3 study in metastatic breast cancer. No Bria-IMT related discontinuations have been reported to date.